公开(公告)号：US20220024918A1

公开(公告)日：2022-01-27

申请号：US17368712

申请日：2021-07-06

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Dong Hoon KIM ,  Su Bin CHOI ,  Sol PARK ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC: C07D471/04 ,  C07D519/00

Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20210317110A1

公开(公告)日：2021-10-14

申请号：US17208887

申请日：2021-03-22

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Su Bin CHOI ,  Sol PARK ,  Dong Hoon KIM ,  So Young KIM ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA ,  Eui Chul LEE

IPC: C07D409/04 ,  C07D409/14 ,  C07D498/04 ,  C07D413/14 ,  C07D471/04 ,  C07D405/14

Abstract: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g. for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20200223808A1

公开(公告)日：2020-07-16

申请号：US16721020

申请日：2019-12-19

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Su Bin CHOI ,  Dong Hoon KIM ,  Sol PARK ,  Eun Hye JUNG ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC: C07D249/08 ,  C07D401/04 ,  C07D403/04 ,  C07D417/04 ,  C07D409/10 ,  C07D405/10 ,  C07D407/14 ,  C07D401/10 ,  C07D403/10 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D413/10 ,  C07D417/10 ,  C07D249/12 ,  C07D403/14

Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20190322655A1

公开(公告)日：2019-10-24

申请号：US16359985

申请日：2019-03-20

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Su Bin CHOI ,  Sol PARK ,  Dong Hoon KIM ,  So Young KIM ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA ,  Eui Chul LEE

IPC: C07D409/04 ,  C07D409/14 ,  C07D405/14 ,  C07D413/14 ,  C07D471/04 ,  C07D498/04

Abstract: The present technology provides triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20190308944A1

公开(公告)日：2019-10-10

申请号：US16359984

申请日：2019-03-20

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Su Bin CHOI ,  Dong Hoon KIM ,  Sol PARK ,  Eun Hye JUNG ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC: C07D249/08 ,  C07D401/04 ,  C07D403/04 ,  C07D417/04 ,  C07D409/10 ,  C07D405/10 ,  C07D413/10 ,  C07D401/10 ,  C07D403/10 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D407/14

Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20170152241A9

公开(公告)日：2017-06-01

申请号：US14893517

申请日：2014-05-23

Applicant: YUHAN CORPORATION

Inventor： Jae Young SIM ,  Myung Hun CHA ,  Tae Kyun KIM ,  Young Ae YOON ,  Dong Hoon KIM

IPC: C07D403/04 ,  C07D409/14 ,  C07D401/04

CPC classification number: C07D403/04 ,  C07D401/04 ,  C07D409/14

Abstract: The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-HT4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like.

公开(公告)号：US20160090374A1

公开(公告)日：2016-03-31

申请号：US14893517

申请日：2014-05-23

Applicant: YUHAN CORPORATION

Inventor： Jae Young SIM ,  Myung CHA ,  Tae Kyun KIM ,  Young Ae YOON ,  Dong Hoon KIM

IPC: C07D403/04 ,  C07D409/14 ,  C07D401/04

CPC classification number: C07D403/04 ,  C07D401/04 ,  C07D409/14

Abstract: The present invention provides: a bicyclic derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof; a preparation method therefor, a pharmaceutical composition comprising the same; and a use therefor. According to the present invention, the bicyclic compound derivative comprising a pyrimidine ring, or a pharmaceutically acceptable salt thereof acts as a 5-HT4 receptor agonist, and thus can be usefully applied to the prevention or treatment of dysfunction in gastrointestinal motility, for example, gastrointestinal diseases such as gastroesophageal reflux disease (GERD), constipation, irritable bowel syndrome (IBS), dyspepsia, post-operative ileus, delayed gastric emptying, gastroparesis, intestinal pseudo-obstruction, drug-induced delayed transit, diabetic gastric atony and the like.

Abstract translation: 本发明提供：包含嘧啶环的双环衍生物或其药学上可接受的盐; 其制备方法，包含其的药物组合物; 并为此使用。 根据本发明，包含嘧啶环的双环化合物衍生物或其药学上可接受的盐用作5-HT 4受体激动剂，因此可用于预防或治疗胃肠蠕动功能障碍，例如， 消化道疾病如胃食管反流病（GERD），便秘，肠易激综合征（IBS），消化不良，手术后肠梗阻，胃排空，胃轻瘫，肠道假性梗阻，药物诱导的延迟转运，糖尿病性胃痛等 。

公开(公告)号：US20210147368A1

公开(公告)日：2021-05-20

申请号：US17104557

申请日：2020-11-25

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Su Bin CHOI ,  Dong Hoon KIM ,  Sol PARK ,  Eun Hye JUNG ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC: C07D249/08 ,  C07D401/04 ,  C07D403/04 ,  C07D417/04 ,  C07D409/10 ,  C07D405/10 ,  C07D407/14 ,  C07D401/10 ,  C07D403/10 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14 ,  C07D413/14 ,  C07D413/10 ,  C07D417/10 ,  C07D249/12 ,  C07D403/14

Abstract: The present technology provides aryl or heteroaryl triazolone derivatives or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and the use thereof. The aryl or heteroaryl triazolone derivatives or their pharmaceutically acceptable salts exhibit selective inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).

公开(公告)号：US20200223844A1

公开(公告)日：2020-07-16

申请号：US16712673

申请日：2019-12-12

Applicant: YUHAN CORPORATION

Inventor： Tae Dong HAN ,  Hee Jae TAK ,  Eun Kyung KIM ,  Dong Hoon KIM ,  Su Bin CHOI ,  Sol PARK ,  Hyun Ho CHOI ,  Tae Wang KIM ,  Mi Kyeong JU ,  Na Ry HA

IPC: C07D471/04 ,  C07D519/00

Abstract: The present technology provides triazolopyridin-3-ones or pharmaceutically acceptable salts thereof, preparation processes thereof, pharmaceutical compositions comprising the same, and uses thereof. The triazolopyridin-3-ones or their pharmaceutically acceptable salts exhibit inhibitory activity on VAP-1 and therefore can be usefully applied, e.g., for the treatment and prophylaxis of nonalcoholic hepatosteatosis (NASH).